CoChat

Why do so many clinical trials of therapies for Alzheimer's disease fail?

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(17)32399-1

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 17 references

Cited by

See all 250

Metadata

Authors
Anderson, R. M., Hadjichrysanthou, C., Evans, S., & Wong, M. M.
Affiliations
Imperial College London (GB)
Corresponding author
Anderson, Roy M
Venue
The Lancet
Publisher
Elsevier BV
Published
2017-11
Volume
390
Issue
10110
Pages
2327-2329
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2769095960
Cited by
228
References
17
Citations by year
2026: 12 · 2025: 18 · 2024: 22 · 2023: 26 · 2022: 40 · 2021: 25 · 2020: 47 · 2019: 25 · 2018: 13
FWCI
17.21
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute on Aging (U01AG016976)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Keywords
Alzheimer's disease, clinical trial failure, trial design, statistical power, surrogate endpoints, composite endpoints, mild cognitive impairment, dementia progression, amyloid-beta, tau pathology
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Clinical Trials as Topic, Female, Humans, Male, Antipsychotic Agents, Treatment Failure, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Why do so many clinical trials of therapies for Alzheimer's disease fail? https://app.cochat.ai/papers/10.1016/s0140-6736(17)32399-1
The paper
Anderson, R. M., Hadjichrysanthou, C., Evans, S., & Wong, M. M. (2017). Why do so many clinical trials of therapies for Alzheimer's disease fail? The Lancet. https://doi.org/10.1016/s0140-6736(17)32399-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.